Dr. Rahul Yande

Most women with genitourinary syndrome of menopause require two to three IntimaLase GSMCare laser sessions to achieve the best sustained improvement in their symptoms. The sessions are spaced four to six weeks apart to allow the tissue's collagen remodelling and regeneration response to develop fully between treatments. Each individual session takes approximately twenty minutes. The treatment is performed in the clinic at Shri Kripalu Hospital, Asef Nagar, Beed. No anaesthesia is required, and most women describe the sensation during the procedure as mild warmth or a gentle pressure. There is no downtime after each session. Women can return to normal daily activities immediately, and there are no restrictions on routine physical activity after treatment. The improvement in symptoms is typically noticed gradually over the weeks following the first and second sessions, as the tissue regeneration progresses. Dryness reduces, lubrication improves, and the burning or discomfort during intimacy diminishes as the mucosal quality is restored. A maintenance session once a year after the initial course is typically recommended to sustain the results, since the underlying hormonal change at menopause is a permanent one and the tissue does not produce its own oestrogen to maintain the regenerated state independently. I discuss the full treatment plan, expected outcomes, and maintenance schedule with every patient at the initial consultation at Shri Kripalu Hospital, Beed.

Laser treatment and topical oestrogen therapy work by different mechanisms, and for many women in my practice in Beed, the best outcome comes from using both together rather than choosing one over the other. Topical oestrogen therapy, applied directly to the vaginal tissue as a cream, ring, or tablet, works by replacing the oestrogen that has been lost at menopause. It restores the vaginal tissue's responsiveness to oestrogen, increasing mucosal thickness, lubrication, and the restoration of normal vaginal pH. It is an evidence-based, effective treatment and is safe for the vast majority of women, including most women with a history of breast cancer when used at the low local doses prescribed for vaginal atrophy. IntimaLase GSMCare laser treatment works differently. Rather than replacing the missing hormone, it delivers a controlled photothermal stimulus to the vaginal mucosa that activates the tissue's own collagen remodelling and regenerative response. The tissue rebuilds itself through its own biological repair mechanisms. Laser treatment is particularly valuable for women who cannot or prefer not to use hormonal therapy, and it can be combined with topical oestrogen in women who want a more comprehensive approach. In my practice at Shri Kripalu Hospital, Beed, I assess each patient's clinical history, symptoms, hormonal status, and any contraindications before recommending whether laser alone, topical oestrogen alone, or a combination approach is the most appropriate management plan.

Yes. IntimaLase GSMCare is a well-established, non-invasive laser treatment with a strong safety profile for the management of genitourinary syndrome of menopause. The procedure is performed without anaesthesia, causes no significant discomfort during or after the session, and requires no downtime. Women can return to their normal daily activities immediately after each treatment. The laser delivers controlled photothermal energy to the vaginal mucosa, which stimulates collagen remodelling and mucosal regeneration in the tissue itself. It does not burn or damage the tissue; it uses a precisely controlled thermal stimulus to trigger the body's own tissue repair and regeneration process. I have been providing IntimaLase GSMCare at Shri Kripalu Hospital, Asef Nagar, Beed, as part of my gynaecological and intimate wellness practice, and the most consistent feedback I receive from patients is that the procedure is far more comfortable than they expected and the improvement in their symptoms is meaningful and sustained. The treatment is not appropriate for women with active vaginal infection, certain gynaecological conditions, or who are pregnant, and this is why a thorough clinical assessment before treatment is essential. Any contraindications are identified at the consultation, and the treatment plan is personalised based on each patient's specific clinical picture.

Genitourinary syndrome of menopause, which I refer to as GSM in my practice at Shri Kripalu Hospital, Asef Nagar, Beed, is the medical name for the set of vaginal, vulvar, and urinary symptoms that develop as oestrogen levels decline during and after menopause. Oestrogen is the hormone responsible for maintaining the health, moisture, thickness, and elasticity of the vaginal lining. It also maintains the normal acidic pH of the vaginal environment, which protects against infection, and the integrity of the tissue around the urethra and bladder. When oestrogen falls at menopause, all of these tissues change together: the vaginal lining becomes thinner, drier, and more fragile; the protective bacterial balance is disrupted; and the urethral and bladder tissue becomes more reactive. The result is a pattern of symptoms that includes vaginal dryness, a burning or sandpaper sensation, pain or discomfort during intimacy, light bleeding after intercourse, and urinary symptoms including urgency, frequency, and recurrent urinary tract infections. The most important thing I want women in Beed and across Marathwada to understand is that GSM is not a normal consequence of ageing that has to be accepted. It is the predictable, specific consequence of a hormonal change, and it has safe and effective treatment available locally.